View of Efficacy, safety and regulatory aspects of orphan drugs for rare diseases: Zolgensma®’s case study | Iberoamerican Journal of Health Law

← Efficacy, safety and regulatory aspects of orphan drugs for rare diseases: Zolgensma®’s case study